FrancophonIA/ELRC3.0 huggingface dataset:
English: What Irbesartan BMS looks like and contents of the pack Irbesartan BMS 75 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side.
Danish: Irbesartan BMSs udseende og pakningstørrelse Irbesartan BMS 75 mg filmovertrukne tabletter er hvide til mathvide, bikonvekse og ovale med et hjerte præget på den ene side og nummeret 2871 på den anden side.
English: What Irbesartan BMS looks like and contents of the pack Irbesartan BMS 300 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side.
Danish: Irbesartan BMSs udseende og pakningstørrelse Irbesartan BMS 300 mg tabletter er hvide til mathvide, bikonvekse og ovale med et hjerte præget på den ene side og nummeret 2773 på den anden side.
English: What Irbesartan BMS looks like and contents of the pack Irbesartan BMS 150 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side.
Danish: Irbesartan BMSs udseende og pakningstørrelse Irbesartan BMS 150 mg filmovertrukne tabletter er hvide til mathvide, bikonvekse og ovale med et hjerte præget på den ene side og nummeret 2872 på den anden side.
English: What Irbesartan BMS looks like and contents of the pack Irbesartan BMS 150 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side.
Danish: Irbesartan BMSs udseende og pakningstørrelse Irbesartan BMS 150 mg tabletter er hvide til mathvide, bikonvekse og ovale med et hjerte præget på den ene side og nummeret 2772 på den anden side.
English: CONDITIONS OF THE MARKETING AUTHORISATION
Danish: DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF
English: EU/1/06/375/016 - 14 tablets EU/1/06/375/017 - 28 tablets EU/1/06/375/018 - 56 tablets EU/1/06/375/019 - 56 x 1 tablets EU/1/06/375/020 - 84 tablets EU/1/06/375/021 - 98 tablets
Danish: EU/1/06/375/016 - 14 tabletter EU/1/06/375/017 - 28 tabletter EU/1/06/375/018 - 56 tabletter EU/1/06/375/019 - 56 x 1 tabletter EU/1/06/375/020 - 84 tabletter EU/1/06/375/021 - 98 tabletter
English: EU/1/06/375/022 - 14 tablets EU/1/06/375/023 - 28 tablets EU/1/06/375/024 - 56 tablets EU/1/06/375/025 - 56 x 1 tablets EU/1/06/375/026 - 84 tablets EU/1/06/375/027 - 98 tablets
Danish: EU/1/06/375/022 - 14 tabletter EU/1/06/375/023 - 28 tabletter EU/1/06/375/024 - 56 tabletter EU/1/06/375/025 - 56 x 1 tabletter EU/1/06/375/026 - 84 tabletter EU/1/06/375/027 - 98 tabletter
English: Excipient: 51.00 mg of lactose monohydrate per film-coated tablet.
Danish: Hjælpestof: 51,00 mg lactosemonohydrat per tablet.
English: Irbesartan BMS prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Danish: Irbesartan BMS forebygger at angiotensin-II binder sig til disse receptorer.
English: EU/1/06/375/006 - 14 tablets EU/1/06/375/007 - 28 tablets EU/1/06/375/008 - 56 tablets EU/1/06/375/009 - 56 x 1 tablets EU/1/06/375/010 - 98 tablets
Danish: EU/1/06/375/006 - 14 tabletter EU/1/06/375/007 - 28 tabletter EU/1/06/375/008 - 56 tabletter EU/1/06/375/009 - 56 x 1 tabletter EU/1/06/375/010 - 98 tabletter
English: EU/1/06/375/028 - 14 tablets EU/1/06/375/029 - 28 tablets EU/1/06/375/030 - 56 tablets EU/1/06/375/031 - 56 x 1 tablets EU/1/06/375/032 - 84 tablets EU/1/06/375/033 - 98 tablets
Danish: EU/1/06/375/028 - 14 tabletter EU/1/06/375/029 - 28 tabletter EU/1/06/375/030 - 56 tabletter EU/1/06/375/031 - 56 x 1 tabletter EU/1/06/375/032 - 84 tabletter EU/1/06/375/033 - 98 tabletter
English: EU/1/06/375/001 - 14 tablets EU/1/06/375/002 - 28 tablets EU/1/06/375/003 - 56 tablets EU/1/06/375/004 - 56 x 1 tablets EU/1/06/375/005 - 98 tablets
Danish: EU/1/06/375/001 - 14 tabletter EU/1/06/375/002 - 28 tabletter EU/1/06/375/003 - 56 tabletter EU/1/06/375/004 - 56 x 1 tabletter EU/1/06/375/005 - 98 tabletter
English: MARKETING AUTHORISATION NUMBERS EU/1/06/375/001-005
Danish: EU/1/06/375/001-005
English: Sun
Danish: Ti
English: Pack size
Danish: Emballage
English: Strength Pharmaceutical Form Route of Administration Immediate Packaging
Danish: 0,2 mg Granulat til oral suspension
English: Protection starts from 25 days after the last injection and lasts for at least a year.
Danish: Beskyttelsen begynder at virke 25 dage efter den sidste injektion og holder et år.
English: The European Commission granted a marketing authorisation valid throughout the EU for ZULVAC 8 Bovis on 15 January 2010.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for ZULVAC 8 Bovis den 15. januar 2010.
English: After the second injection, animals may show a slight, temporary increase in body temperature of 0.4 ºC, in the 24 hours after vaccination.
Danish: Efter den anden injektion kan der forekomme en forbigående, mindre stigning i dyrenes kropstemperatur på 0,4 ºC inden for 24 timer efter vaccinationen.
English: ZULVAC 8 Bovis was initially authorised under ‘exceptional circumstances'.
Danish: ZULVAC 8 Bovis blev oprindeligt godkendt under "særlige omstændigheder".
English: The first injection is given from three months of age and the second injection is given three weeks later.
Danish: Den første injektion gives, når dyret er tre måneder gammelt, og den anden injektion gives tre uger senere.
English: The withdrawal period for ZULVAC 8 Bovis for meat and milk is zero days.
Danish: Tilbageholdelsestiden for ZULVAC 8 Bovis for kød og mælk er nul dage.
English: The vaccine is given to animals as an injection in the muscle.
Danish: Vaccinen gives til dyr ved injektion i musklerne.
English: In the future, if the animals are exposed to the bluetongue virus the immune system will be able to produce antibodies more quickly.
Danish: Hvis dyrene efterfølgende udsættes for bluetongue-vira, vil immunsystemet hurtigere kunne danne antistoffer mod dem.
English: In 2013 the CVMP considered that the submitted data were adequate for the authorisation of ZULVAC 8 Bovis to convert to a normal status.
Danish: I 2013 konkluderede CVMP, at de forelagte oplysninger var tilstrækkelige for at kunne omdanne godkendelsen af ZULVAC 8 Bovis til en normal godkendelse.
English: Results from a series of laboratory safety trials performed with a vaccine of similar composition containing serotypes 1 and 8 and of studies performed with a vaccine of the same composition but of different serotype, used in sheep were presented in order to extrapolate safety conclusions.
Danish: Der blev fremlagt resultater fra en række laboratoriesikkerhedsundersøgelser, der blev gennemført med en vaccine af tilsvarende sammensætning indeholdende serotype 1 og 8, samt resultater fra undersøgelser, som blev gennemført med en vaccine af samme sammensætning, men med forskellig serotype.
English: Inactivated vaccine against Bluetongue virus, serotype 8
Danish: Inaktiveret vaccine mod bluetongue-virus, serotype 8
English: Another laboratory study looked at the duration of the immunity following vaccination with ZULVAC 8 Bovis.
Danish: I en anden laboratorieundersøgelse så man på immunitetens varighed efter vaccination med ZULVAC 8 Bovis.
English: The efficacy of the vaccine in cattle was studied in a laboratory trial using the vaccine in calves from two and a half months of age.
Danish: Vaccinens virkning hos kvæg blev undersøgt i en laboratorieundersøgelse, hvor vaccinen blev brugt til kalve i alderen to og en halv måned og derover.
English: The safety of the vaccine was studied in laboratory safety studies carried out with ZULVAC 8 Bovis in cattle.
Danish: Vaccinens sikkerhed blev undersøgt i laboratoriesikkerhedsundersøgelser, som blev gennemført med ZULVAC 8 Bovis hos kvæg.
English: The studies showed that the vaccine is safe for cattle and that it prevents viraemia in animals from three months of age that are infected with bluetongue virus serotype 8.
Danish: Det fremgik af undersøgelserne, at vaccinen er sikker for kvæg, og at den forebygger viræmi hos dyr i alderen tre måneder og derover, som er smittet med bluetongue-virus, serotype 8.
English: The vaccine is used to prevent viraemia (the presence of the virus in the blood) in cattle from three months of age.
Danish: Vaccinen anvendes til at forebygge viræmi (tilstedeværelse af virus i blodet) hos kvæg i alderen tre måneder og derover.
English: ZULVAC 8 Bovis contains bluetongue virus of one type (serotype 8).
Danish: ZULVAC 8 Bovis indeholder bluetongue-vira af én type (serotype 8).
English: This means that it was not possible to obtain complete information about ZULVAC 8 Bovis at the time of the initial authorisation.
Danish: Det betyder, at det på tidspunktet for den oprindelige godkendelse ikke var muligt at indhente fyldestgørende oplysninger om ZULVAC 8 Bovis.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ZULVAC 8 Bovis exceed the risks in the prevention of viraemia caused by the bluetongue virus serotype 8 in cattle from three months of age.
Danish: Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved ZULVAC 8 Bovis opvejer risiciene ved forebyggelse af viræmi forårsaget af bluetongue-virus, serotype 8, hos kvæg i alderen tre måneder og derover.
English: ZULVAC 8 Bovis is a vaccine.
Danish: ZULVAC 8 Bovis er en vaccine.
English: ZULVAC 8 Bovis is used in cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
Danish: ZULVAC 8 Bovis anvendes til kvæg som beskyttelse mod sygdommen bluetongue, en infektion forårsaget af bluetongue-virus, der overføres gennem mitter.
English: ZULVAC 8 Bovis contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
Danish: ZULVAC 8 Bovis indeholder bluetongue-vira, som er blevet inaktiveret, så de ikke kan fremkalde sygdommen.
English: It contains inactivated (killed) bluetongue serotype 8 virus.
Danish: Den indeholder inaktiveret (dræbt) bluetongue-virus, serotype 8.
English: Other information about ZULVAC 8 Bovis:
Danish: Andre oplysninger om ZULVAC 8 Bovis:
English: ZULVAC 8 Bovis is a vaccine that is available as a suspension for injection.
Danish: ZULVAC 8 Bovis er en vaccine, der fås som en suspension til injektion.
English: What is the risk associated with ZULVAC 8 Bovis?
Danish: Hvilken risiko er der forbundet med ZULVAC 8 Bovis?
English: Why has ZULVAC 8 Bovis been approved?
Danish: Hvorfor blev ZULVAC 8 Bovis godkendt?
English: What is ZULVAC 8 Bovis?
Danish: Hvad er ZULVAC 8 Bovis?
English: How has ZULVAC 8 Bovis been studied?
Danish: Hvordan blev ZULVAC 8 Bovis undersøgt?
English: What is ZULVAC 8 Bovis used for?
Danish: Hvad anvendes ZULVAC 8 Bovis til?
English: How does ZULVAC 8 Bovis work?
Danish: Hvordan virker ZULVAC 8 Bovis?
English: What benefit has ZULVAC 8 Bovis shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved ZULVAC 8 Bovis?
English: H-2100 Gödöllő
Danish: H-2100 Gödöllö
English: Zoledronic acid was administered once a year, until at least 211 patients in the study population had confirmed clinical fractures.
Danish: Zoledronsyre blev administreret en gang årligt, indtil mindst 211 patienter i forsøgspopulationen havde bekræftede kliniske frakturer.
English: It must not be mixed or given intravenously with any other medicinal products.
Danish: Det må ikke blandes eller gives intravenøst sammen med andre lægemidler.
English: Table 2 Summary of vertebral fracture efficacy at 12, 24 and 36 months Outcome
Danish: Tabel 2 Resumé af effekt på vertebrale frakturer ved 12, 24 og 36 måneder Resultat
English: Date of first authorisation: 16 August 2012 Date of latest renewal:
Danish: Dato for første markedsføringstilladelse: 16. august 2012 Dato for seneste fornyelse:
English: Very common Pyrexia
Danish: Meget almindelig Pyreksi
English: Zoledronic acid Teva Pharma may work for longer than one year, and your doctor will let you know if you need to be treated again.
Danish: Zoledronsyre Teva Pharma kan virke i mere end et år, og din læge vil fortælle dig, om du skal behandles igen.
English: Thus these results precluded determining a definitive effect of zoledronic acid on fertility in humans.
Danish: Derfor forhindrede disse resultater bestemmelse af zoledronsyre definitive effekt på fertilitet i mennesker.
English: Follow carefully all instructions given to you by your doctor or nurse.
Danish: Følg nøje alle instruktioner, du får af lægen eller sundhedspersonalet.
English: - you are taking medicines called corticosteroids (such as prednisolone or dexamethasone) - you have cancer.
Danish: - du tager medicin kaldet kortikosteroider (fx prednisolon eller dexamethason) - du har kræft.
English: Other products containing zoledronic acid as an active substance are available for oncology indications.
Danish: Andre produkter, der indeholder zoledronsyre som aktivt stof, fås til onkologiindikationer.
English: • Key signs and symptoms of serious adverse events • When to seek attention from the health care provider
Danish: • Væsentlige tegn og symptomer på alvorlige bivirkninger • Hvornår det er nødvendigt at opsøge sundhedspersonale.
English: Italia Teva Italia S.r.l.
Danish: Teva Italia S.r.l.
English: • Contraindication in pregnancy and in breast-feeding women due to potential teratogenicity
Danish: • Kontraindikationer hos gravide og ammende kvinder grundet potentiel teratogenicitet
English: The incidence rates of key clinical fracture variables are presented in Table 4.
Danish: Incidensraten af vigtige kliniske frakturvariabler er angivet i tabel 4.
English: The educational programme contains the following:
Danish: Uddannelsesprogrammet skal indeholde følgende:
English: This leaflet was last revised in {MM/YYYY}
Danish: Denne indlægsseddel blev senest ændret <{MM/ÅÅÅÅ}>
English: The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of Zoledronic acid Teva Pharma on an individual patient basis, particularly after 5 or more years of use.
Danish: Behovet for fortsat behandling skal revurderes regelmæssigt, baseret på fordele og mulige risici af Zoledronsyre Teva Pharma for den enkelte patient, især efter anvendelse i 5 år eller mere.
English: If you feel dizzy while taking Zoledronic acid Teva Pharma, do not drive or use machines until you feel better.
Danish: Hvis du føler dig svimmel, mens du tager Zoledronsyre Teva Pharma, må du ikke køre bil eller betjene maskiner, før du har det bedre.
English: If you missed a dose of Zoledronic acid Teva Pharma Contact your doctor or hospital as soon as possible to re-schedule your appointment.
Danish: Hvis du har glemt en dosis Zoledronsyre Teva Pharma Kontakt din læge eller dit hospital så hurtigt som muligt for at få en ny tid.
English: • A single dose of Zoledronic acid Teva Pharma should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Danish: • En enkelt dosis Zoledronsyre Teva Pharma bør ikke overstige 5 mg, og infusionsvarigheden bør være mindst 15 minutter (se pkt.
English: • Physician educational material
Danish: • lægeundervisningsmateriale
English: Observed in patients taking concomitant glucocorticosteroids.
Danish: Observeret i patienter, der samtidigt tager glukokortikoider.
English: It is currently unclear whether Zoledronic acid Teva Pharma causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic acid Teva Pharma.
Danish: Det er på nuværende tidspunkt uklart, om Zoledronsyre Teva Pharma forårsager denne uregelmæssige hjerterytme, men du skal kontakte din læge, hvis du oplever sådanne symptomer, efter du har fået Zoledronsyre Teva Pharma.
English: Patients being treated with Zoledronic acid Teva Pharma should not be treated with such products or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Danish: Patienter, der behandles med Zoledronsyre Teva Pharma, bør ikke behandles med sådanne produkter eller andre bisfosfonater samtidig, da den kombinerede effekt af disse lægemidler er ukendt.
English: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as a result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Danish: • når risikostyringssystemet ændres, særlig som følge af, at der er modtaget nye oplysninger, der kan medføre en væsentlig ændring i risk/benerfit-forholdet, eller som følge af, at en vigtig milepæl (lægemiddelovervågning eller risikominimering) er nået.
English: Uncommon Hypertension, flushing Not known** Hypotension (some of the patients had underlying risk factors)
Danish: Ikke almindelig Forhøjet blodtryk, rødmen Hypotension (nogle af patienterne havde underliggende risikofaktorer)
English: This is especially important for the elderly (≥ 65 years) and for patients receiving diuretic therapy.
Danish: Dette gælder specielt for ældre patienter (≥ 65 år) og for patienter, som er i behandling med diuretika.
English: Ask your doctor, pharmacist or nurse for advice before using this medicine.
Danish: Spørg din læge, farmaceuten eller sundhedspersonalet til råds, før du bruger dette lægemiddel.
English: In another study in men (study CZOL446M2308) an annual infusion of zoledronic acid was noninferior to weekly alendronate for the percentage change in lumbar spine BMD at month 24 relative to baseline.
Danish: I et andet studie, som omfattede mænd, (studie CZOL446M2308) var en årlig infusion af zoledronsyre non-inferiør i forhold til ugentlig alendronat for den procentuelle ændring i lænderyg-BMD ved måned 24 i forhold til baseline.
English: Before stopping Zoledronic acid Teva Pharma therapy If you are considering stopping Zoledronic acid Teva Pharma treatment, please go to your next appointment and discuss this with your doctor.
Danish: Før Zoledronsyre Teva Pharma-behandlingen stoppes Hvis du overvejer at stoppe Zoledronsyre Teva Pharma-behandlingen, bedes du gå til din næste tid og drøfte det med lægen.
English: Tell your doctor and dentist immediately if you experience such symptoms while being treated with Zoledronic acid Teva Pharma or after stopping treatment.
Danish: Kontakt straks din læge og tandlæge, hvis du oplever sådanne symptomer, mens du er i behandling med Zoledronsyre Teva Pharma, eller efter at behandlingen er stoppet.
English: The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Pharma can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Pharma administration.
Danish: Incidensen af post-dosis-symptomer, der opstår inden for de første tre dage efter administration af Zoledronsyre Teva Pharma, kan reduceres ved at administrere paracetamol eller ibuprofen kort efter administration af Zoledronsyre Teva Pharma.
English: The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic acid Teva Pharma.
Danish: Størstedelen af bivirkningerne, såsom feber og kulderystelser, smerter i muskler eller led og hovedpine, opstår inden for de første tre dage efter en dosis Zoledronsyre Teva Pharma.
English: The MAH must agree the content and format of the educational material, together with a communication plan, with the national competent authorities in
Danish: Indehaveren af markedsføringstilladelsen skal aftale informationsmaterialets indhold og format samt en kommunikationsplan med de kompetente nationale myndigheder i medlemslandene før distribution af uddannelsesprogrammet.
English: Not known** Hypersensitivity reactions including rare cases of bronchoconstriction, urticaria and angioedema, and very rare cases of anaphylactic reaction/shock
Danish: Hypersensitivitetsreaktioner inklusive sjældne tilfælde af bronkokonstriktion, urticaria og angioødem og meget sjældne tilfælde af anafylaktisk reaktion/shock
English: Special populations Patients with renal impairment
Danish: Særlige populationer Patienter med nedsat nyrefunktion
English: For the treatment of post-menopausal osteoporosis, osteoporosis in men and the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy, the recommended dose is a single intravenous infusion of 5 mg Zoledronic acid Teva Pharma administered once a year.
Danish: Til behandling af postmenopausal osteoporose, osteoporose hos mænd og behandling af osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling er den anbefalede dosis en enkelt intravenøs infusion af 5 mg Zoledronsyre Teva Pharma administreret en gang om året.
English: • Patient educational material
Danish: • patientundervisningsmateriale.
English: At 24 months a similar significant increase of 3.6% in total hip BMD was observed for patients treated with zoledronic acid as compared to the effects observed in postmenopausal women in the HORIZON-PFT study.
Danish: Ved 24 måneder blev der observeret en signifikant øgning på 3,6 % i BMD over hele hoften hos patienter, som blev behandlet med zoledronsyre, svarende til effekten observeret hos postmenopausale kvinder i HORIZON-PFT studiet.
English: C-reactive protein increased Uncommon Blood calcium decreased
Danish: Stigning i C-reaktivt protein Ikke almindelig Nedsat calcium i blodet
English: • Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Zoledronic acid Teva Pharma.
Danish: • Patienter, specielt ældre patienter og patienter i behandling med diuretika, bør være passende hydreret forud for behandling med Zoledronsyre Teva Pharma.
English: • Transient increase in serum creatinine may be greater in patients with underlying impaired renal
Danish: • Forbigående øgning i serumkreatinin kan være højere hos patienter med underliggende
English: Not known** Renal impairment.
Danish: Ikke kendt**
English: Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Danish: Intravenøst administreret zoledronsyre elimineres i en trifasisk proces: hurtig bifasisk elimination fra det systemiske kredsløb med halveringstider på t½ 0,24 og t½β 1,87 timer efterfulgt af en lang elimineringsfase med en terminal eliminationshalveringstid på t½γ 146 timer.
English: Limited data on re-treatment of Paget's disease are available (see section 5.1).
Danish: Der er begrænsede tilgængelige data om efterbehandlingen af Pagets sygdom (se pkt.
English: Bone biopsies were obtained from the iliac crest 1 year after the third annual dose in 152 post-menopausal patients with osteoporosis treated with zoledronic acid (N=82) or placebo (N=70).
Danish: Der blev udført biopsier fra crista iliaca 1 år efter den tredje årlige dosis på 152 postmenopausale patienter med osteoporose behandlet med zoledronsyre (N=82) eller placebo (N=70).
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu..
Danish: Yderligere information om dette lægemiddel er tilgængeligt på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
English: Zoledronic acid Teva Pharma works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
Danish: Zoledronsyre Teva Pharma virker ved at normalisere remodelleringsprocessen, sikre dannelse af normalt knoglevæv og dermed genoprette knoglestyrken.
English: • Need to ensure appropriate hydration of the patient especially those at an advanced age and those receiving diurectic therapy
Danish: • Nødvendigheden af at sikre passende hydrering af patienten specielt ældre patienter og patienter i diuretisk behandling